OCSL Stock Analysis: Oaktree Specialty Lending | NASDAQ
Asset Management | NASDAQ, USA | Market Cap: 1.044m USD | 12M Return: 4.5% | US67401P4054 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.16M
EPS Trend: -97.6%
Qual. Beats: 0
Rev. Trend: 4.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oaktree Specialty Lending Corporation (OCSL) is a business development company (BDC) that provides financing solutions to small and mid-sized companies, primarily in North America. Its investment approach centers on middle-market lending, offering structures such as first and second lien debt, bridge financing, mezzanine loans, senior and junior secured debt, preferred equity, and one-stop financing, often with an equity co-investment component. The firm typically participates in expansions, sponsor-led acquisitions, and management buyouts, with a stated preference for acting as lead investor in its portfolio companies.
OCSL invests across a diversified range of industries, including education, business and consumer services, healthcare, manufacturing, food and restaurants, construction and engineering, media, software, IT services, pharmaceuticals, biotechnology, real estate, chemicals, machinery, and internet retail. As a BDC, the company operates under a regulatory framework that generally requires it to distribute the majority of its taxable income to shareholders, and its external manager is affiliated with Oaktree Capital Management, a global alternative investment firm.
- Floating-rate loan income tracks SOFR rate movements
- Non-accruals rise as middle-market borrowers face credit pressure
- Direct lending competition pressures spreads on new originations
| Net Income: 42.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.97 > 1.0 |
| NWC/Revenue: -116.9% < 20% (prev 74.66%; Δ -191.6% < -1%) |
| CFO/TA 0.10 > 3% & CFO 277.6m > Net Income 42.2m |
| Net Debt (1.40b) to EBITDA (224.3m): 6.24 < 3 |
| Current Ratio: 0.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.1m) vs 12m ago 0.0% < -2% |
| Gross Margin: 80.54% > 18% (prev 22.69%; Δ 57.85% > 0.5%) |
| Asset Turnover: 9.59% > 50% (prev 5.32%; Δ 4.27% > 0%) |
| Interest Coverage Ratio: 1.20 > 6 (EBIT TTM 123.0m / Interest Expense TTM 102.5m) |
| A: -0.11 (Total Current Assets 107.7m - Total Current Liabilities 434.0m) / Total Assets 2.86b |
| B: -0.34 (Retained Earnings -967.9m / Total Assets 2.86b) |
| C: 0.04 (EBIT TTM 123.0m / Avg Total Assets 2.91b) |
| D: 0.94 (Book Value of Equity 1.38b / Total Liabilities 1.48b) |
| Altman-Z'' = -0.58 = B |
As of October 08, 2026, the stock is trading at USD 11.65 with a total of 455,092 shares traded. Over the past week, the price has changed by -2.10%, over one month by -6.34%, over three months by -0.58% and over the past year by +4.47%.
Current recommended Stop Loss: 11.20 (which is 3.9% or 1.9 ATR below the current price).
Oaktree Specialty Lending has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold OCSL.
- StrongBuy: 0
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.5 | 7.3% |
P/E Trailing = 24.6875
P/E Forward = 8.9445
P/S = 3.5719
P/B = 0.7745
P/EG = 0.9343
Revenue TTM = 279.1m USD
EBIT TTM = 123.0m USD
EBITDA TTM = 224.3m USD
Long Term Debt = unknown (none)
Short Term Debt = 96.8m USD (from shortTermDebt, last fiscal year)
Debt = 1.44b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.40b USD (calculated: Debt 1.44b - CCE 39.9m)
Enterprise Value = 2.44b USD (1.04b + Debt 1.44b - CCE 39.9m)
Interest Coverage Ratio = 1.20 (Ebit TTM 123.0m / Interest Expense TTM 102.5m)
EV/FCF = 8.80x (Enterprise Value 2.44b / FCF TTM 277.6m)
FCF Yield = 11.36% (FCF TTM 277.6m / Enterprise Value 2.44b)
FCF Margin = 99.45% (FCF TTM 277.6m / Revenue TTM 279.1m)
Net Margin = 15.13% (Net Income TTM 42.2m / Revenue TTM 279.1m)
Gross Margin = 80.54% ((Revenue TTM 279.1m - Cost of Revenue TTM 54.3m) / Revenue TTM)
Gross Margin QoQ = 60.84% (prev 86.31%)
Tobins Q-Ratio = 0.85 (Enterprise Value 2.44b / Total Assets 2.86b)
Interest Expense / Debt = 7.12% (Interest Expense 102.5m / Debt 1.44b)
Taxrate = 5.57% (2.49m / 44.7m)
NOPAT = 116.2m (EBIT 123.0m * (1 - 5.57%))
Current Ratio = 0.25 (Total Current Assets 107.7m / Total Current Liabilities 434.0m)
Debt / Equity = 1.04 (Debt 1.44b / totalStockholderEquity, last quarter 1.38b)
Debt / EBITDA = 6.24 (Net Debt 1.40b / EBITDA 224.3m)
Debt / FCF = 5.04 (Net Debt 1.40b / FCF TTM 277.6m)
Total Stockholder Equity = 1.42b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.45% (Net Income 42.2m / Total Assets 2.86b)
RoE = 2.98% (Net Income TTM 42.2m / Total Stockholder Equity 1.42b)
RoCE = 5.08% (EBIT 123.0m / Capital Employed (Total Assets 2.86b - Current Liab 434.0m))
RoIC = 3.99% (NOPAT 116.2m / Invested Capital 2.91b)
WACC = 7.16% (E(1.04b)/V(2.48b) * Re(7.75%) + D(1.44b)/V(2.48b) * Rd(7.12%) * (1-Tc(0.06)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.02 | Cagr: 4.51%
[DCF] Terminal Value 77.97% ; FCFF base≈258.3m ; Y1≈296.1m ; Y5≈435.9m
[DCF] Fair Price = 58.58 (EV 6.56b - Net Debt 1.40b = Equity 5.16b / Shares 88.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -97.60 | EPS CAGR: -17.19% | SUE: 0.29 | # QB: 0
Revenue Correlation: 4.90 | Revenue CAGR: 1.36% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.34 | Chg30d=-1.55% | Revisions=-17% | Analysts=6
EPS current Year (2026-09-30): EPS=1.50 | Chg30d=+0.27% | Revisions=+0% | GrowthEPS=-14.8% | GrowthRev=-10.2%
EPS next Year (2027-09-30): EPS=1.36 | Chg30d=-0.75% | Revisions=+0% | GrowthEPS=-9.2% | GrowthRev=+0.2%
[Analyst] Revisions Ratio: -7% (up=5, down=6)